Literature DB >> 30764666

Intestinal phosphate absorption: The paracellular pathway predominates?

Matthew Saurette1,2, R Todd Alexander1,2,3.   

Abstract

IMPACT STATEMENT: This review summarizes the work on transcellular intestinal phosphate absorption, arguing why this pathway is not the predominant pathway in humans consuming a "Western" diet. We then highlight the recent evidence which is strongly consistent with paracellular intestinal phosphate absorption mediating the bulk of intestinal phosphate absorption in humans.

Entities:  

Keywords:  Phosphate; gut; intestine; nephrology; paracellular; transport

Mesh：

Substances：

Year:  2019        PMID： 30764666      PMCID： PMC6552399          DOI： 10.1177/1535370219831220

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN： 1535-3699


  88 in total

1.  Expression of type II Na-P(i) cotransporter in alveolar type II cells.

Authors:  M Traebert; O Hattenhauer; H Murer; B Kaissling; J Biber
Journal:  Am J Physiol       Date:  1999-11

2.  Claudin extracellular domains determine paracellular charge selectivity and resistance but not tight junction fibril architecture.

Authors:  Oscar R Colegio; Christina Van Itallie; Christoph Rahner; James Melvin Anderson
Journal:  Am J Physiol Cell Physiol       Date:  2003-04-16       Impact factor: 4.249

Review 3.  Intraluminal pH of the human gastrointestinal tract.

Authors:  J Fallingborg
Journal:  Dan Med Bull       Date:  1999-06

4.  Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine.

Authors:  K Katai; H Tanaka; S Tatsumi; Y Fukunaga; K Genjida; K Morita; N Kuboyama; T Suzuki; T Akiba; K Miyamoto; E Takeda
Journal:  Nephrol Dial Transplant       Date:  1999-05       Impact factor: 5.992

5.  Transepithelial resistance can be regulated by the intestinal brush-border Na(+)/H(+) exchanger NHE3.

Authors:  J R Turner; E D Black; J Ward; C M Tse; F A Uchwat; H A Alli; M Donowitz; J L Madara; J M Angle
Journal:  Am J Physiol Cell Physiol       Date:  2000-12       Impact factor: 4.249

6.  Intestinal NaCl transport in NHE2 and NHE3 knockout mice.

Authors:  Lara R Gawenis; Xavier Stien; Gary E Shull; Patrick J Schultheis; Alison L Woo; Nancy M Walker; Lane L Clarke
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-05       Impact factor: 4.052

7.  NAD+ ameliorates inflammation-induced epithelial barrier dysfunction in cultured enterocytes and mouse ileal mucosa.

Authors:  Xiaonan Han; Takashi Uchiyama; Penny L Sappington; Arino Yaguchi; Runkuan Yang; Mitchell P Fink; Russell L Delude
Journal:  J Pharmacol Exp Ther       Date:  2003-09-15       Impact factor: 4.030

8.  Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

Authors:  Tobias Larsson; Ulf Nisbeth; Osten Ljunggren; Harald Jüppner; Kenneth B Jonsson
Journal:  Kidney Int       Date:  2003-12       Impact factor: 10.612

Review 9.  The sodium phosphate cotransporter family SLC34.

Authors:  Heini Murer; Ian Forster; Jürg Biber
Journal:  Pflugers Arch       Date:  2003-05-16       Impact factor: 3.657

10.  Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

Authors:  Yutaka Takahashi; Araki Tanaka; Tsukasa Nakamura; Tsutomu Fukuwatari; Katsumi Shibata; Noriaki Shimada; Isao Ebihara; Hikaru Koide
Journal:  Kidney Int       Date:  2004-03       Impact factor: 10.612
View more
  5 in total

1.  Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).

Authors:  Geoffrey A Block; Anthony J Bleyer; Arnold L Silva; Daniel E Weiner; Robert I Lynn; Yang Yang; David P Rosenbaum; Glenn M Chertow
Journal:  Kidney360       Date:  2021-08-27

Review 2.  Intestinal phosphorus absorption: recent findings in translational and clinical research.

Authors:  Kathleen M Hill Gallant; Colby J Vorland
Journal:  Curr Opin Nephrol Hypertens       Date:  2021-07-01       Impact factor: 3.416

3.  A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).

Authors:  Pablo E Pergola; David P Rosenbaum; Yang Yang; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2021-03-25       Impact factor: 14.978

Review 4.  Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review.

Authors:  Steven N Fishbane; Sagar Nigwekar
Journal:  Kidney Med       Date:  2021-08-27

Review 5.  Phosphate Frustration: Treatment Options to Complement Current Therapies.

Authors:  Pablo E Pergola
Journal:  Int J Nephrol       Date:  2022-08-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.